Pacritinib Citrate

Tier C — Watch / trade

Pacritinib Citrate

S*BIO Pte Ltd

Originator

2022

First approval

Expiry (public)

$0.14B ▲

Peak sales

Small molecule

Type

Targets：JAK2, JAK2 V617F, FLT3, IRAK1, ACVR1, CSF1R

Brand：Epjevy, ENPAXIQ, VONJO

Indications (approved)：Myelofibrosis

Regional status

Approved

2022-02-28

Phase III

2013-01-01

China

Japan

Phase III

2017-06-26

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield /

PACR-00197-51-8PACR-002107-04-0PACR-003110837-53-1PACR-004937273-30-8PACR-005106-95-6PACR-006937273-31-9PACR-0071312603-46-5PACR-008937273-29-5PACR-009—PACR-010123-75-1PACR-0113934-20-1PACR-01287199-15-3PACR-013859517-90-1API · Pacritinib Citrate

Code	CAS No.	Intermediate
PACR-001	97-51-8	2-hydroxy-5-nitrobenzaldehyde
PACR-002	107-04-0	1-bromo-2-chloroethane
PACR-003	110837-53-1 Available	2-(2-chloroethoxy)-5-nitrobenzaldehyde
PACR-004	937273-30-8	(2-(2-chloroethoxy)-5-nitrophenyl)methanol
PACR-005	106-95-6 Available	3-bromoprop-1-ene
PACR-006	937273-31-9 Available	2-((allyloxy)methyl)-1-(2-chloroethoxy)-4-nitrobenzene
PACR-007	1312603-46-5	3-((allyloxy)methyl)-4-(2-chloroethoxy)aniline
PACR-008	937273-29-5 Available	4-(3-((allyloxy)methyl)phenyl)-2-chloropyrimidine
PACR-009	-	-
PACR-010	123-75-1	pyrrolidine
PACR-011	3934-20-1 Available	2,4-dichloropyrimidine
PACR-012	87199-15-3	(3-(hydroxymethyl)phenyl)boronic acid
PACR-013	859517-90-1 Available	(3-(2-chloropyrimidin-4-yl)phenyl)methanol

OptimisedRoute 2Steps 4 · Total yield /

PACR-006937273-31-9PACR-008937273-29-5PACR-010123-75-1PACR-014937273-32-0PACR-015937273-33-1PACR-016937273-34-2API · Pacritinib Citrate

Code	CAS No.	Intermediate
PACR-006	937273-31-9 Available	2-((allyloxy)methyl)-1-(2-chloroethoxy)-4-nitrobenzene
PACR-008	937273-29-5 Available	4-(3-((allyloxy)methyl)phenyl)-2-chloropyrimidine
PACR-010	123-75-1	pyrrolidine
PACR-014	937273-32-0	1-(2-(2-((allyloxy)methyl)-4-nitrophenoxy)ethyl)pyrrolidine
PACR-015	937273-33-1 Available	3-((allyloxy)methyl)-4-(2-(pyrrolidin-1-yl)ethoxy)aniline
PACR-016	937273-34-2	N-(3-((allyloxy)methyl)-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-4-(3-((allyloxy)methyl)phenyl)pyrimidin-2-amine

Frequently asked questions

What are the approved indications of Pacritinib Citrate?

Approved indications include: Myelofibrosis.

When does the Pacritinib Citrate patent expire?

No public expiry year is available for Pacritinib Citrate yet; this page updates once verified.

How many synthesis routes are recorded for Pacritinib Citrate?

2 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Pacritinib Citrate intermediates?

7 intermediate CAS of Pacritinib Citrate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Pacritinib Citrate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29